Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Mayer L, Kappos L, Racke MK, Rammohan K, Traboulsee A, Hauser SL, et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Scler Relat Disord. 2019;30:236–43.
2. Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A, et al. Best practices for long-term monitoring and follow-up of alemtuzumab-treated MS patients in real-world clinical settings. Front Neurol. 2019;10:253.
3. Fernández O. Best practice in the use of natalizumab in multiple sclerosis. Ther Adv Neurol Disord. 2013;6(2):69–79.
4. Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C, Häring DA, et al. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. J Comp Eff Res. 2020;9(18):1255–74.
5. Biogen Idec. Tysabri® (natalizumab) 150 mg solution for injection in pre-filled syringe summary of product characteristics; 2021. Available from: https://www.medicines.org.uk/emc/product/12443/smpc#about-medicine.